MedTrace Logo

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2021-09-05

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

Tropifexor (LJN452)

Comparison of different doses of drug

DRUG

Placebo

Comparator

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2020-04-06
Completion
2020-04-06
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Netherlands
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855164 on ClinicalTrials.gov